Israel’s VBL Therapeutics announced that it does not plan to continue development of its VB-201 for treatment of patients with psoriasis and ulcerative colitis (UC). The company said that its Phase II studies evaluating its lead Lecinoxoid compound VB-201 in patients with psoriasis and UC did not meet their primary …